Comparative Pharmacology
Head-to-head clinical analysis: APONVIE versus MAXOLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APONVIE versus MAXOLON.
APONVIE vs MAXOLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
APONVIE (pemigatinib) is a selective fibroblast growth factor receptor (FGFR) inhibitor. It binds to and inhibits FGFR1, FGFR2, and FGFR3, thereby suppressing FGFR signaling and reducing proliferation and survival of tumor cells with FGFR alterations.
Metoclopramide, the active ingredient in MAXOLON, is a dopamine D2 receptor antagonist and also enhances the response to acetylcholine at muscarinic receptors in the gastrointestinal tract, leading to increased gastric motility and accelerated gastric emptying. It also has antiemetic effects by blocking dopamine receptors in the chemoreceptor trigger zone (CTZ).
APONVIE is not a recognized drug; no dosing information available.
10 mg orally, intramuscularly, or intravenously three to four times daily. Maximum daily dose: 30 mg or 0.5 mg/kg.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours in healthy adults; prolonged to 24–36 hours in severe renal impairment (CrCl <30 mL/min).
5-6 hours in adults with normal renal function; prolonged to 15-20 hours in severe renal impairment (CrCl <10 mL/min).
APONVIE is primarily excreted renally as unchanged drug (approx. 70%) and via biliary/fecal routes (approx. 30%).
Renal: 85-95% as unchanged drug and metabolites; biliary/fecal: <5%.
Category C
Category C
Antiemetic
Antiemetic